ArticleJournal of the National Cancer Institute2020
Re: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Paolo Giorgi Rossi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.